Changes in Plasma ACTH Levels and Corticotroph Tumor Size in Patients With Cushing's Disease During Long-term Treatment With the Glucocorticoid Receptor Antagonist Mifepristone

Maria Fleseriu; James W. Findling; Christian A. Koch; Sven-Martin Schlaffer; Michael Buchfelder; Coleman Gross

首页> 外文期刊>The journal of clinical endocrinology and metabolism >Changes in Plasma ACTH Levels and Corticotroph Tumor Size in Patients With Cushing's Disease During Long-term Treatment With the Glucocorticoid Receptor Antagonist Mifepristone

【24h】

Changes in Plasma ACTH Levels and Corticotroph Tumor Size in Patients With Cushing's Disease During Long-term Treatment With the Glucocorticoid Receptor Antagonist Mifepristone

机译：糖皮质激素受体拮抗剂米非司酮长期治疗库欣病患者血浆ACTH水平和皮质激素肿瘤大小的变化

获取原文

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

页面导航

摘要
著录项
相似文献
相关主题

摘要

Context:Pituitary effects of long-term therapy with mifepristone, a glucocorticoid receptor antagonist, in Cushing's disease (CD) patients are not well understood.

机译：背景：米色普司酮（一种糖皮质激素受体拮抗剂）长期治疗对库欣病（CD）患者的垂体作用尚未完全了解。

著录项

来源
《The journal of clinical endocrinology and metabolism》 |2014年第10期|共10页
作者
Maria Fleseriu; James W. Findling; Christian A. Koch; Sven-Martin Schlaffer; Michael Buchfelder; Coleman Gross;
展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种
中图分类代谢病;
关键词

相似文献

外文文献
中文文献
专利

1. Changes in Plasma ACTH Levels and Corticotroph Tumor Size in Patients With Cushing's Disease During Long-term Treatment With the Glucocorticoid Receptor Antagonist Mifepristone [J] . Maria Fleseriu, James W. Findling, Christian A. Koch, The journal of clinical endocrinology and metabolism . 2014,第10期

机译：糖皮质激素受体拮抗剂米非司酮长期治疗库欣病患者血浆ACTH水平和皮质激素肿瘤大小的变化
2. Serum levels of tumor necrosis factor-alpha, soluble intercellular adhesion molecule-1, soluble vascular cell adhesion molecule-1, and soluble interleukin-1 receptor antagonist in patients with thyroid eye disease undergoing treatment with somatostat [J] . Krassas GE, Pontikides N, Doukidis D, Thyroid: official journal of the American Thyroid Association . 2001,第12期

机译：接受甲状腺抑素治疗的甲状腺疾病患者的血清肿瘤坏死因子-α，可溶性细胞间粘附分子-1，可溶性血管细胞粘附分子-1和可溶性白介素-1受体拮抗剂的水平
3. Plasma histamine levels (H) during adjunctive H1-receptor antagonist treatment with loratadine in patients with active inflammatory bowel disease (IBD). [J] . Raithel M, Nagel A, Zopf Y, Inflammation research: Official journal of the European Histamine Research Society . 2010,第Suppla2期

机译：活动性肠炎（IBD）患者接受氯雷他定辅助H1受体拮抗剂辅助治疗期间的血浆组胺水平（H）。
4. Differential Effects of the New GlucocorticoidReceptor Antagonist ORG 34517 and RU486(Mifepristone) on Glucocorticoid ReceptorNuclear Translocation in the AtT20 Cell Line [C] . B.W.M.M. Peeters, G.S.F. Ruigt, M. Craighead, International Symposium on Catecholamines and Other Neurotransmitters in Stress . 2008

机译：新型糖皮质激素拮抗剂组织组织拮抗剂组织术的差异效应和ru486（MIFEPRISTONE）对ATT20细胞系糖皮质激素的糖皮质激素核易位
5. Plasma aldosterone levels increase after cerebral ischemia, and mineralocorticoid receptor antagonism at the time of reperfusion reduces infarct size; the role of mineralocorticoid receptor antagonism on the inflammatory response post-stroke. [D] . Dams Ramos, Carla Maria. 2012

机译：脑缺血后血浆醛固酮水平增加，再灌注时盐皮质激素受体拮抗作用减少了梗塞面积；盐皮质激素受体拮抗作用对中风后炎症反应的作用。
6. Changes in Plasma ACTH Levels and Corticotroph Tumor Size in Patients With Cushings Disease During Long-term Treatment With the Glucocorticoid Receptor Antagonist Mifepristone [O] . Maria Fleseriu, James W. Findling, Christian A. Koch, -1

机译：糖皮质激素受体拮抗剂米非司酮长期治疗库欣病患者血浆ACTH水平和皮质激素肿瘤大小的变化
7. Efficacy of 12-month treatment with the GH receptor antagonist pegvisomant in patients with acromegaly resistant to long-term, high-dose somatostatin analog treatment: effect on IGF-I levels, tumor mass, hypertension and glucose tolerance [O] . Annamaria Colao, Rosario Pivonello, Renata S Auriemma, 2006

机译：12个月治疗与GH受体拮抗剂PEG血征在长期高剂量的高剂量患者患者中的疗效，对IGF-I水平，肿瘤质量，高血压和葡萄糖耐量的影响

Changes in Plasma ACTH Levels and Corticotroph Tumor Size in Patients With Cushing's Disease During Long-term Treatment With the Glucocorticoid Receptor Antagonist Mifepristone

摘要

著录项

相似文献

相关主题

期刊订阅